INTS

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer treatments. The company's lead product candidate is designed to be injected directly into tumors, where it disperses throughout the tumor and kills cancer cells while activating the immune system to attack the cancer. Intensity Therapeutics is advancing its drug candidate through clinical trials for various solid tumor types. The company's technology platform aims to address limitations of traditional systemic cancer therapies by delivering high concentrations of drug directly to the tumor site.